Hi @A.B.
This is where the genetic part of the studies are likely to come into play.
I am in total agreement with Ron that strongest signals would logically be expected to be found in the most severely ill. What is the basis of your argument for the strongest signal (as opposed to just a signal) being in families? If they are all mild, that may not be so. The SD's may not be far from the norm unlike the recent Naviaux study, and Whitney for example.
I agree that families diagnosed with ME/CFS would be a very important study. Especially from a genetic perspective. I would love to see it run. It all comes down to funding, this is all still publically funded so while I am sure Ron would like to do a study on families with ME/CFS, there is only a limited pot to go round.
I will note this down as I think its a really good, interesting question and if Ron has the time, I'd love to see his answer.
Thanks,
B
And Dr Avi Nath of the NIH study thinks it's most important to look at those closest to the trigger, which is why that study is looking at post-infectious patients in the first few years (5, right?) He has described it as needing to know where the epicenter of the earthquake is, rather than where the devastation is greatest.
I think there's a rationale for all, and all should be studied. I'd love to see a family study - I think it's important, particularly given the rituximab findings.
I think we could get really key information from each of these extreme groups - families, severe and early. A potential difficulty with looking at early patients is that you will have more of a mix of those who are going to improve and those who are not going to improve, which could muddy the data. So there's a rationale for focusing on long duration patients too! We won't know where the biomarkers are strongest until we look. In many autoimmune diseases, some people can be symptomatic for many years before any of the biomarkers for their autoimmune disease show up, if they show up...